1 Study Matches
Site for A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
Atopic Dermatitis: Double Blind, 4 weeks study. Topical Cream applied daily. Males/Females 2-5 years with mild to moderate atopic dermatitis. At the week 4 visit subjects may be eligible to enroll in a 12-month, open label extension study. The goal of the study is assess the safety and effectiveness of ARQ-151 0.05% cream.
Younger than 18 years old
Inclusion Criteria:Must be 2-5 years of age
Exclusion Criteria:certain medications/treatments are not allowed; study coordinator will discuss further
Subjects currently undergoing allergy testing (food allergy testing or skin prick testing), patch testing, food challenges, or allergy desensitization, or plan to do so during the study